[1] Pagliusi SR,Teresa Aguado M.Efficacy and other milestones for human papillomavirus vaccine introduction.Vaccine,2004,23(5):569-578. [2] Micheletti F,Bazzaro M,Canella A,et al.The lifespan of major histocompatibility complex class 1/peptide complexes determines the efficiency of cytotoxic T-lymphocyte responses.Immunology,1999,96(3):411-415. [3] Bullock TN,Colella TA,Engelhard VH.The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gpl00 in HLA-A2 transgenic mice.J Immunol,2000,164(5):2354-2361. [4] 尹锐,郝飞,郝进,等.人乳头瘤病毒16E7限制性细胞毒性T细胞表位的穿膜肽疫苗设计及体外免疫学研究.临床皮肤科杂志,2005,34(12):807-809. [5] 尹锐,郝飞,钟白玉,等.特异性HPVl6E7 CTL表位肽-MHC I复合物单抗的制备及鉴定.中华实验和病毒学杂志,2006,20(3):257-259. [6] Sette A,Fikes J.Epitope-based vaccines:an update on epitope identification,vaccine design and delivery.Curr Opin Immunol,2003,15(4):461-470. [7] 尹锐,郝飞,郝进,等.HIV Tat49-57增强人乳头瘤病毒16E7细胞毒性T细胞表位穿膜效应研究.中华皮肤科杂志,2006,39(5):285-288. |